EGFL6 and neoplasm: Moreover, we developed an anti-EGFL6 antibody, EGFL6-E5-IgG, to verify the anti-tumor, anti-metastatic and anti-angiogenic properties in vivo to validate the potential of EGFL6 as a therapeutic target in CRC.